Origin and biologic function of Reed-Sternberg cells

  • R. I. Fisher
  • S. E. Bates
  • D. J. Volkman
  • V. Diehl
  • T. T. Hecht
  • D. L. Longo
Part of the Developments in Oncology book series (DION, volume 32)


For many years it has been well known that untreated patients with Hodgkin’s disease of all stages had significant impairment of their cellular immune response, as manifested in vivo by impaired delayed hypersensitivity skin tests, and in vitro by decreased E rosette formation as well as decreased T-cell proliferation in response to mitogens or antigens. Abnormalities of cellular immunity were always more pronounced in patients with advanced stages of disease. In contrast, significant abnormalities of humoral immunity have not been detected. These early studies have been reviewed in detail [1, 2].


Proliferative Response L428 Cell Accessory Cell Mixed Lymphocyte Reaction L428 Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kaplan HS (1980). Hodgkin’s Disease. Cambridge, Mass.: Harvard University Press.Google Scholar
  2. 2.
    Twomey JJ and Rice L (1980). Impact of Hodgkin’s disease upon the immune system. Semin Oncol 7: 114–125.PubMedGoogle Scholar
  3. 3.
    Bobrove AM, Fuks Z, Strober S and Kaplan HS (1975). Quantitation of T and B lymphocytes and cellular immune function in Hodgkin’s disease. Cancer 36: 169–179.PubMedCrossRefGoogle Scholar
  4. 4.
    Posner MR, Reinherz EL, Berard J et al. (1981). Lymphoid subpopulations of peripheral blood and spleen in untreated Hodgkin’s disease. Cancer 48: 1170–1176.PubMedCrossRefGoogle Scholar
  5. 5.
    Goodwin JS, Messner RP and Peake GT (1977). Prostaglandin producing suppressor cells in Hodgkin’s disease. N Engl J Med 297: 963–968.PubMedCrossRefGoogle Scholar
  6. 6.
    Twomey JJ, Laughter AH and Farrow S (1975). Hodgkin’s disease: An immunodepleting and immunosuppressive disorder. J Clin Invest 56: 467–475.PubMedCrossRefGoogle Scholar
  7. 7.
    Engleman EG, Benike C and Hoppe RT (1979). Suppressor cells of the mixed lymphocyte reaction in patients with Hodgkin’s disease. Transplant Proc 4: 1827–1829.Google Scholar
  8. 8.
    Hellinger SM and Herzig GP (1978). Impaired cell-mediated immunity in Hodgkin’s disease mediated by suppressor lymphocytes and monocytes. J Clin Invest 61: 1620–1627.CrossRefGoogle Scholar
  9. 9.
    Fuks Z, Strober S and Kaplan HS (1976). Interaction between serum factors and T-lymphocytes in Hodgkin’s disease: Use as a diagnostic test. N Engl J Med 295: 1273–1278.PubMedCrossRefGoogle Scholar
  10. 10.
    Fuks Z, Strober S and King DP (1976). Reversal of cell surface abnormalities of T-lymphocytes in Hodgkin’s disease after in vitroincubation in fetal sera. J Immunol 117: 1331–1335.PubMedGoogle Scholar
  11. 11.
    Deshazo RD, Ewel C, Londono S et al. (1981). Evidence for the involvement of monocyte-derived toxic oxygen metabolites in the lymphocyte dysfunction of Hodgkin’s disease. Clin Exp Immunol 46: 313–320.PubMedGoogle Scholar
  12. 12.
    Fisher RI and Bostick-Bruton F (1982). Depressed T-cell proliferative responses in Hodgkin’s disease: Role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide. J Immunol 129: 1770–1774.PubMedGoogle Scholar
  13. 13.
    Fisher RI, Vanhaelen C and Bostick F (1981). Increased sensitivity to normal adherent suppressor cells in advanced Hodgkin’s disease. Blood 57: 830–835.PubMedGoogle Scholar
  14. 14.
    Vanhaelen CPJ and Fisher RI (1981), Increased sensitivity of lymphocytes from patients with Hodgkin’s disease to concanavalin A-induced suppressor cells. J Immunol 127: 1216–1220.PubMedGoogle Scholar
  15. 15.
    Fisher RI (1982). Implications of persistent T-cell abnormalities for the etiology of Hodgkin’s disease. Cancer Treat Rep 66: 681–688.PubMedGoogle Scholar
  16. 16.
    Schaadt N, Diehl V, Stein H et al. (1980). Two neoplastic cell lines with unique features derived from Hodgkin’s disease. Int J Cancer 26: 723–731.PubMedCrossRefGoogle Scholar
  17. 17.
    Diehl V, Kirchner HH, Burrichter H et al. (1982). Characteristics of Hodgkin derived cell lines. Cancer Treat Rep 66: 615–632.PubMedGoogle Scholar
  18. 18.
    Fisher RI, Bostick-Bruton F, Sauder DN et al. (1983). Neoplastic cells obtained from Hodgkin’s disease are potent stimulators of human primary mixed lymphocyte cultures. J Immunol 130: 2666–2670.PubMedGoogle Scholar
  19. 19.
    Fisher RI, Bates SE, Bostick-Bruton F et al (1984). Neoplastic cells obtained from Hodgkin’s disease function as accessory cells for mitogen-induced human T-cell proliferative responses. J Immunol 132: 2672–2677.PubMedGoogle Scholar
  20. 20.
    Fisher RI, Diehl V and Volkman DJ (1984). Hodgkin’s disease is a tumor of antigen-presenting cells. Proc Amer Assoc Cancer Res 25: 193.Google Scholar
  21. 21.
    Van Voorhis WC, Hair LS, Steinman RN and Kaplan G (1982). Human dendritic cells. Enrichment and characterization from peripheral blood. J Exp Med 155: 1172–1187.PubMedCrossRefGoogle Scholar
  22. 22.
    Van Voorhis WC, Hair LS, Steinman RN and Kaplan G (1982). Human dendritic cells. Enrichment and characterization from peripheral blood. J Exp Med 155: 1172–1187.PubMedCrossRefGoogle Scholar
  23. 23.
    Schwab U, Stein H, Gerdes J et al. (1982). Production of a monoclonal antibody specific for Hodgkin’s and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature 299: 65–67.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • R. I. Fisher
    • 1
  • S. E. Bates
    • 1
  • D. J. Volkman
    • 2
  • V. Diehl
    • 3
  • T. T. Hecht
    • 1
  • D. L. Longo
    • 1
  1. 1.Medicine BranchNational Cancer InstituteBethesdaUSA
  2. 2.National Institute of Allergy and Infectious DiseasesBethesdaUSA
  3. 3.Medizinische HochschuleHannoverGermany

Personalised recommendations